A patient with a phaeochromocytoma and severe left ventricular heart failure caused by a catecholamine-induced cardiomyopathy is described. The clinical signs of congestive heart failure resolved rapidly on treatment with captopril and myocardial performance became normal within two weeks of medical treatment with captopril for one week and with captopril in combination with phenoxybenzamine for another week. (Br Heart J 1992;68:527-8) figure) .
.
During the next two days the patient's blood pressure fluctuated considerably. On the third day extubation could be performed and treatment with vasopressors was stopped. The patient became again hypertensive; systolic blood pressure peaked at over 230 mm Hg. Medical treatment with diuretics and nifedipine was unsuccessful. Captopril, however, controlled blood pressure and improved the clinical signs of left ventricular failure within eight hours.
A tenfold increase in the catecholamine concentration in a 24 hour urinary sample confirmed the suspected phaeochromocytoma. A computer tomogram of the abdomen showed a mass of 5-5 x 3 5 cm in diameter in the region of the left adrenal gland. This mass was the only area to show increased uptake of '35I-meta-iodobenzyl-guanidine. The appearance of the endomyocardial biopsy specimen was consistent with a catecholamine-induced cardiomyopathy. One week later treatment with captopril was started and the patient was also given increasing doses of the ac antagonist, phenoxybenzamine (up to 60 mg a day). A week later, a radionuclide angiocardiography showed a complete normal myocardial performance and the calculated ejection fraction was 65%.
The phaeochromocytoma was removed one week later without complication. One week after operation the serum and urinary concentrations of catecholamines were within the normal ranges. The hypothesis is supported by published experimental data. Hu showed that captopril inhibited the development of the catecholamine-induced cardiomyopathy in rats with phaeochromocytomas.9 It is unlikely that this effect was the result of captopril's antihypertensive efficacy, because the non-specific vasodilator hydralazine has no effect on the development of catecholamine-induced cardiomyopathy though it normalised blood pressure in the same rats.'0 The difference between captopril and hydralazine can be explained by their different influences on the local cardiac renin-angiotensin system." Angiotensin increases the growth and proliferation rate of myocytes in vitro. Hydralazine activates mycocytological renin activity, which in turn stimulates cardiac hypertrophy. In contrast, captopril inhibits the cardiac renin-angiotensin axis." This is one possible mechanism, by which captopril may counteract catecholamine-induced cardiomyopathy. Furthermore, free radicals from long chain fatty acids, which act as direct myocardial toxins, have been described in phaeochromocytoma.'2 Captopril, an angotensin converting enxyme inhibitor with sulphydryl groups, may be able to scavenge these free radicals."
Discussion
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